Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population

[1] Thorpe LM(2015)PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting Nat Rev Cancer 15 7-24

[2] Yuzugullu H(2012)The biological role of PI3K pathway in lung cancer Pharmaceuticals (Basel) 5 1236-1264

[3] Zhao JJ(2018)The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress J Cell Biochem 119 213-222

[4] Sarris EG(2008)Rare PIK3CA hotspot mutations in carcinomas of the biliary tract Genes Chromosomes Cancer 47 363-367

[5] Saif MW(2008)Mutations of the PIK3CA gene in diffuse large B cell lymphoma Diagn Mol Pathol 17 159-165

[6] Syrigos KN(2020)A systematic literature review of the prognostic and predictive value of PIK3CA mutations in HR(+)/HER2(-) metastatic breast cancer Clin Breast Cancer 20 e232-e243

[7] Bahrami A(2019)Alpelisib: first global approval Drugs 79 1249-1253

[8] Khazaei M(2015)In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer Anticancer Res 35 175-182

[9] Shahidsales S(2021)Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: a Chinese pan-cancer cohort J Cell Mol Med 25 10279-10290

[10] Hassanian SM(2014)Trimmomatic: a flexible trimmer for Illumina sequence data Bioinformatics (Oxford, England) 30 2114-2120

[1] Thorpe LM(2015)PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting Nat Rev Cancer 15 7-24

[2] Yuzugullu H(2012)The biological role of PI3K pathway in lung cancer Pharmaceuticals (Basel) 5 1236-1264

[3] Zhao JJ(2018)The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress J Cell Biochem 119 213-222

[4] Sarris EG(2008)Rare PIK3CA hotspot mutations in carcinomas of the biliary tract Genes Chromosomes Cancer 47 363-367

[5] Saif MW(2008)Mutations of the PIK3CA gene in diffuse large B cell lymphoma Diagn Mol Pathol 17 159-165

[6] Syrigos KN(2020)A systematic literature review of the prognostic and predictive value of PIK3CA mutations in HR(+)/HER2(-) metastatic breast cancer Clin Breast Cancer 20 e232-e243

[7] Bahrami A(2019)Alpelisib: first global approval Drugs 79 1249-1253

[8] Khazaei M(2015)In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer Anticancer Res 35 175-182

[9] Shahidsales S(2021)Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: a Chinese pan-cancer cohort J Cell Mol Med 25 10279-10290

[10] Hassanian SM(2014)Trimmomatic: a flexible trimmer for Illumina sequence data Bioinformatics (Oxford, England) 30 2114-2120